Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer [0.03%]
对“接受放疗和度伐利尤单抗治疗的局部晚期非小细胞肺癌患者放射性肺炎的相关临床及剂量体积因素”的勘误发表
Hiroto Inoue,Akira Ono,Takanori Kawabata et al.
Hiroto Inoue et al.
Published Erratum
Investigational new drugs. 2021 Jun;39(3):899. DOI:10.1007/s10637-020-00969-4 2021
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer [0.03%]
LY3023414治疗癌症患者的I期剂量递增研究
Shunsuke Kondo,Masaomi Tajimi,Tomohiko Funai et al.
Shunsuke Kondo et al.
LY3023414 is an oral, selective adenosine triphosphate-competitive inhibitor of class I phosphatidylinositol 3-kinase isoforms, mammalian target of rapamycin, and DNA-protein kinase in clinical development. We report results of a 3 + 3 dose...
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma [0.03%]
BI 836826（CD37抗体）治疗复发或难治性B细胞非霍奇金淋巴瘤I期爬坡剂量研究的更正公告
Frank Kroschinsky,Jan Moritz Middeke,Martin Janz et al.
Frank Kroschinsky et al.
Published Erratum
Investigational new drugs. 2021 Feb;39(1):285-286. DOI:10.1007/s10637-020-00964-9 2021
Correction to: The old CEACAMs find their new role in tumor immunotherapy [0.03%]
Correction to：古老的CEACAMs在肿瘤免疫治疗中找到新角色
Zi-Wen Han,Zhi-Wu Lyv,Bin Cui et al.
Zi-Wen Han et al.
Correction is needed to the original version of this article.
Published Erratum
Investigational new drugs. 2020 Dec;38(6):1899-1900. DOI:10.1007/s10637-020-00967-6 2020
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434) [0.03%]
Epacadostat单药及其与pembrolizumab联合治疗晚期实体瘤在日本患者中的安全性及耐受性：I期研究（KEYNOTE-434）结果
Toshihiko Doi,Yutaka Fujiwara,Kohei Shitara et al.
Toshihiko Doi et al.
Purpose: Part A of the open-label, phase I KEYNOTE-434 study evaluated the safety and tolerability of epacadostat, an indoleamine 2,3-dioxygenase-1 inhibitor, alone and in combination with pembrolizumab in Japanese patien...
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab [0.03%]
阿法替尼联合贝伐珠单抗治疗奥希替尼耐药的EGFR外显子18(G719S)突变肺腺癌患者一例
Motohiro Tamiya,Kei Kunimasa,Kazumi Nishino et al.
Motohiro Tamiya et al.
Exon 18 mutations account for only 3.6% of EGFR mutations, and tumors with exon 18 mutations are often unresponsive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). We present a novel case of a lung adenocarcino...
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors [0.03%]
替莫唑胺和甲氧胺（TRC-102，一种作用于碱基切除修复的抑制剂）Ⅰ期临床试验：在晚期实体瘤患者中的应用
Jennifer R Eads,Smitha S Krishnamurthi,Joel Saltzman et al.
Jennifer R Eads et al.
Temozolomide (TMZ) generates DNA adducts that are repaired by direct DNA and base excision repair mechanisms. Methoxyamine (MX, TRC-102) potentiates TMZ activity by binding to apurinic and apyrimidinic (AP) sites after removal of N3-methyla...
Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study [0.03%]
艾洛替尼治疗奥希替尼诱发的间质性肺病后的非小细胞肺癌患者的安全性和有效性：一项回顾性研究
Shingo Nasu,Hidekazu Suzuki,Takayuki Shiroyama et al.
Shingo Nasu et al.
Background Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, the occurrence rate of osimertinib-induced interstitial lung di...
First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects [0.03%]
健康志愿者中Selatinib（EGFR-ErbB2双受体抑制剂）单次递增剂量给药I期临床研究：安全性、药代动力学及相对生物利用度
Meng-Na Wang,Yun Kuang,Li-Ying Gong et al.
Meng-Na Wang et al.
We assessed the pharmacokinetics and safety of a single oral administration of selatinib to healthy Chinese subjects and evaluated the potential bioavailability advantage of selatinib relative to lapatinib. Healthy subjects aged 18-40 years...
The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma [0.03%]
肾细胞癌中潜在的治疗靶点动力蛋白KIF4A
Guihong Liu,Yachun Lu,Liantao Li et al.
Guihong Liu et al.
Kinesin family member 4A (KIF4A) is located in the human chromosome band Xq13.1. It has a highly conserved kinesin motor region at its N-terminus, which is followed by a central coiled-coil region and a C-terminus cargo-binding domain that ...